Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab vs Oxycodone and Placebo in Osteoarthritis of the Knee or Hip
NCT00985621Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Oct 2009
- Primary completion
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of tanezumab in osteoarthritis (OA) (4 arms), sponsored by Pfizer. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at 8 weeks. Started Oct 2009; status: terminated.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00985621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00985621.